Ablynx today announced that its partner Boehringer Ingelheim has dosed the first healthy volunteers in a Phase I clinical trial as part of the evaluation of a Nanobody® for the treatment of Alzheimer’s disease. The start of the Phase I study triggers a milestone payment of €5 million to Ablynx.
29 October, 2013
There has been tremendous interest from delegates, poster presenters and exhibitors, following the announcement by ELRIG (the European Laboratory Robotics Interest Group) who will be hosting a unique, 2 day conference entitled ‘Advances in Recombinant Protein Technologies – towards redesigned synthetic systems’. The free to attend conference will be held at Astra Zeneca R&D’s Alderly Park Site on 19th and 20th November and is strictly limited to 220 attendees.
21 October, 2013